KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Operating Leases (2020 - 2025)

Historic Operating Leases for Travere Therapeutics (TVTX) over the last 6 years, with Q3 2025 value amounting to $18.4 million.

  • Travere Therapeutics' Operating Leases fell 2302.96% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year decrease of 2302.96%. This contributed to the annual value of $17.2 million for FY2024, which is 2397.4% down from last year.
  • Travere Therapeutics' Operating Leases amounted to $18.4 million in Q3 2025, which was down 2302.96% from $19.7 million recorded in Q2 2025.
  • Travere Therapeutics' Operating Leases' 5-year high stood at $34.5 million during Q1 2022, with a 5-year trough of $17.2 million in Q4 2024.
  • Moreover, its 5-year median value for Operating Leases was $26.9 million (2022), whereas its average is $26.4 million.
  • As far as peak fluctuations go, Travere Therapeutics' Operating Leases skyrocketed by 1115.54% in 2021, and later tumbled by 2397.4% in 2024.
  • Over the past 5 years, Travere Therapeutics' Operating Leases (Quarter) stood at $31.5 million in 2021, then fell by 12.66% to $27.5 million in 2022, then fell by 17.8% to $22.6 million in 2023, then dropped by 23.97% to $17.2 million in 2024, then rose by 6.91% to $18.4 million in 2025.
  • Its last three reported values are $18.4 million in Q3 2025, $19.7 million for Q2 2025, and $21.0 million during Q1 2025.